Hyperliquid Strategies Inc /
Sonnet BioTherapeutics Holdings, Inc.
Hyperliquid Strategies Inc completes business combination with Sonnet BioTherapeutics Holdings, Inc.
Source for the buyer and target: Sonnet BioTherapeutics Holdings, Inc.
For the buyer and target.
“On December 2, 2025 (the “Closing Date”), Sonnet BioTherapeutics Holdings, Inc. (“Sonnet”) completed its previously announced business combination (the “Closing”), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the “BCA”), by and among the Company, Hyperliquid Strategies Inc (“HSI”), Rorschach I LLC (“Rorschach”), TBS Merger Sub Inc. (“Sonnet Merger Sub”) and Rorschach Merger Sub, LLC (“Rorschach Merger Sub”).”
Published 3 Dec 2025
Open the sourceWhat happened
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. completed their business combination on Dec. 2, 2025. Sonnet is now a wholly owned subsidiary of Hyperliquid Strategies Inc. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Hyperliquid Strategies Inc completes business combination with Sonnet BioTherapeutics Holdings, Inc.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Closed
“Hyperliquid Strategies Inc completes business combination with Sonnet BioTherapeutics Holdings, Inc. Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. completed their business combination on Dec. 2,…”
Open the sourcePublished by Sonnet BioTherapeutics Holdings, Inc.
The source this page is built from.
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly